Recent Analysts’ Ratings Updates for Vanda Pharmaceuticals (VNDA)

A number of research firms have changed their ratings and price targets for Vanda Pharmaceuticals (NASDAQ: VNDA):

  • 8/2/2019 – Vanda Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $14.00 price target on the stock. According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “
  • 8/1/2019 – Vanda Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/1/2019 – Vanda Pharmaceuticals was upgraded by analysts at Citigroup Inc from a “neutral” rating to a “buy” rating. They now have a $19.00 price target on the stock.
  • 7/31/2019 – Vanda Pharmaceuticals had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $17.00 price target on the stock. They wrote, “We are reiterating our Hold rating and $17 target price on VNDA shares as we continue to see limited upside from these levels given a relatively risky pipeline, for which we believe should only be assigned modest value, and a base business that seems more-or-less fully valued. Overall, the quarter looked good with top and bottom line beats driven by Hetlioz and meaningfully lower R&D spend. With that said, 2019 sales guidance for both Hetlioz and Fanapt remain unchanged, though management did update its cash guidance and expects to end 2019 with more cash than previously guided due to the lower spend throughout the year. As we highlighted in our recent deep dive (link here), we see few upside opportunities and more downside risks over the next 12 months and believe the overhang from the FDA lawsuit/tradipitant chronic safety will likely keep shares relatively range bound, in our view.””
  • 7/27/2019 – Vanda Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “
  • 7/24/2019 – Vanda Pharmaceuticals was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $17.00 price target on the stock, down previously from $26.00. They wrote, “We are downgrading VNDA shares to Hold and lowering our target price to $17. Based on our recent diligence, we were overly bullish on thinking VNDA’s pipeline was more de- risked than it really was, and we see the company as highly levered to a base business with limited growth potential. After a more critical look at tradipitant’s clinical data and information disclosed from the FDA lawsuit, we believe there is greater clinical, safety, and timing risk around this program than we previously thought. For the stock, we believe there are more downside risks than upside opportunities over the next 12 months and don’t necessarily view a potential near-term resolution of the FDA lawsuit (win or lose) as a meaningful positive catalyst, given our new found questions about tradipitant’s safety for chronic diseases. We are no doubt late with the stock call here, but better late than never.””
  • 7/5/2019 – Vanda Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “
  • 7/2/2019 – Vanda Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 6/28/2019 – Vanda Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “
  • 6/22/2019 – Vanda Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “

Shares of VNDA traded down $0.28 during mid-day trading on Tuesday, reaching $15.05. The stock had a trading volume of 185,692 shares, compared to its average volume of 896,422. The firm has a market cap of $816.63 million, a price-to-earnings ratio of 31.35 and a beta of 0.38. Vanda Pharmaceuticals Inc. has a 12 month low of $11.83 and a 12 month high of $33.44. The business has a fifty day moving average of $13.97 and a 200 day moving average of $16.63.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.24. Vanda Pharmaceuticals had a return on equity of 10.23% and a net margin of 13.61%. The company had revenue of $59.06 million for the quarter, compared to the consensus estimate of $54.19 million. During the same period in the previous year, the business earned $0.15 EPS. Vanda Pharmaceuticals’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, equities analysts anticipate that Vanda Pharmaceuticals Inc. will post 0.32 earnings per share for the current fiscal year.



In other news, SVP Timothy Williams sold 2,575 shares of the stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $14.69, for a total value of $37,826.75. Following the completion of the transaction, the senior vice president now directly owns 57,425 shares of the company’s stock, valued at approximately $843,573.25. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 8.20% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. United Services Automobile Association raised its stake in Vanda Pharmaceuticals by 5.8% during the 2nd quarter. United Services Automobile Association now owns 14,544 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 792 shares during the period. Voloridge Investment Management LLC raised its stake in Vanda Pharmaceuticals by 16.8% during the 2nd quarter. Voloridge Investment Management LLC now owns 57,793 shares of the biopharmaceutical company’s stock worth $814,000 after buying an additional 8,310 shares during the period. Pictet Asset Management Ltd. raised its stake in Vanda Pharmaceuticals by 28.0% during the 2nd quarter. Pictet Asset Management Ltd. now owns 476,000 shares of the biopharmaceutical company’s stock worth $6,707,000 after buying an additional 104,200 shares during the period. Nuveen Asset Management LLC acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter worth $13,388,000. Finally, UBS Asset Management Americas Inc. raised its stake in Vanda Pharmaceuticals by 89.1% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 34,327 shares of the biopharmaceutical company’s stock worth $484,000 after buying an additional 16,171 shares during the period. 99.33% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

See Also: How interest rates affect municipal bond prices

Receive News & Ratings for Vanda Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.